RS54750B1 - Borati kao inhibitori arginaze - Google Patents

Borati kao inhibitori arginaze

Info

Publication number
RS54750B1
RS54750B1 RS20160243A RSP20160243A RS54750B1 RS 54750 B1 RS54750 B1 RS 54750B1 RS 20160243 A RS20160243 A RS 20160243A RS P20160243 A RSP20160243 A RS P20160243A RS 54750 B1 RS54750 B1 RS 54750B1
Authority
RS
Serbia
Prior art keywords
alkylene
aryl
alkyl
group
branched
Prior art date
Application number
RS20160243A
Other languages
English (en)
Inventor
Zandt Michael Van
Jr Gunnar Erik Jagdmann
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of RS54750B1 publication Critical patent/RS54750B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Jedinjenje Formule I,pri čemuR1je izabrano iz grupe koja se sastoji od -OH, ORa, i NRbRc;Raje izabrano iz grupe koja se sastoji od vodonika, linearnog ili razgranatog (C1-C6)alkila, (C3-C8)cikloalkila, (C3-C14)arila, (C3-C14)heterocikloalkil-( C1- C6)alkilena-, (C3-C14)heteroaril-(C1-C6)alkilena-, i (C3-C14)aril(C1-C6)alkilena-;svaki Rb i Rc je nezavisno izabran iz grupe koja se sastoji od H, -OH, linearnog ili razgranatog (C1-C6)alkila, -SO2-(C1-C6)alkila, (C3-C14)aril-SO2-, (C3-C14)heterocikloalkil-(C1-C6)alkilena-, i (C3-C14)heteroaril-(C1-C6)alkilena-;R2 je izabrano iz grupe koja se sastoji od H, linearnog ili razgranatog (C1-C6) alkila, i (C1-C6)alkil-C(O)-;svaki W, X, Y, i Z je nezavisno izabran iz grupe koja se sastoji od veze, -C(R')(R"')-, -C(R")2-, -CR'"-, -NR'"-, -N-, -O-, -C(O)-, i.-S-, pri čemu više od tri W, X, Y i Z istovremeno ne predstavljaju vezu;i više od dva susedna člana W, X, Y i Z istovremeno nisu -O-, -S-, -N-, ili -NR'"-;l, m, n i p nezavisno su celi brojevi između 0 i 2 uključujući njih, pri čemu najmanje jedan od l, m, n, ili p nije 0;opciono predstavlja jednu ili više dvostrukih veza;svaki R3 i R4 je nezavisno izabran između vodonika, linearnog ili razgranatog (C1-C6)alkila, i C(O)-R',ili R3 i R4zajedno sa atomom bora za koji su vezani obrazuju 5- ili 6-člani prsten kojije potpuno zasićen, ili je delimično zasićen;D je izabrano iz grupe koja se sastoji od linearnog ili razgranatog (C3-C5)alkilena, linearnog ili razgranatog (C2-C8)alkenilena, linearnog ili razgranatog (C2-C8)alkinilena, (C3-C14)arilena, i (C3-C14)cikloalkilena,pri čemu je jedna ili više -CH2- grupa u D opciono i nezavisno zamenjena sa radikalom izabranim iz grupe koja se sastoji od O, NR', S, SO, SO2, i CR'R"; ilipri čemu bilo koje dve susedne -CH2- grupe opciono predstavljaju dva člana (C3-C14)-cikloalkilenil grupe; ipri čemu dve nesusedne -CH2- grupe istovremeno predstavljaju O, NR', S, SO, ili SO2;svaki R', R" i R'" je nezavisno izabran iz grupe koja se sastoji od H, OH, S(O)Rd, S(O)2Rd, (C1-C8)alkila, (C3-C6)arila, -NH2, -NH(C1-C6)alkila, -N[(C1-C6)alkil]2, -C(O)NRdRe, -C(O)( C1-C6)alkila, -C(O)(C3-C14)arila, -C(O)O(C1-C6)alkila, -C(O)O(C3-C14)arila, (C3-C6)cikloalkila, (C3-C14)heterocikloalkila, -C(O)( C3-C14)heterocikloalkila, (C3-C14)heteroarila, (C3-C14)aril-( C1-C6)alkilena-, -C(O) (C3-C14)aril-(C1-C6)alkilena-, -C(O)(C3-C14)arila, (C3-C6)cikloalkil-(C1-C6)alkilena-, (C3-C14)heteroaril-(C1-C6)alkilena-, (C3-C14)heterocikl-(C1-C6)alkilena-; i pri čemu je bilo koji alkil, alkilen, aril, heteroaril, cikloalkil, ili heterocikloalkil opciono supstituisan sa jednim ili više članova izabranih iz grupe koja se sastoji od halogena, okso, -COOH, -CN, -NO2, -OH, -NRdRe, -NRgS(O)2Rh, (C1-C6)alkoksi, (C3-C14)arila, (C1-C6)haloalkila i (C3-C14)ariloksi; pri čemu je svaki Rd, Re, Rg, i Rh nezavisno izabran iz grupe koja se sastoji od H, linearnog ili razgranatog (C1-C6)alkila, opciono supstituisanog (C3-C14)aril(C1-C6)alkilena-, opciono supstituisanog (C3-C14)arila, (C1-C6)hidroksialkila, (C1-C6)aminoalkila, H2N(C1-C6)alkilena-, opciono supstituisanog (C3-C6)cikloalkila, opciono supstituisanog (C3-C14)heterocikloalkila, opciono supstituisanog (C3-C14)heteroarila, opciono supstituisanog (C3-C14)aril-(C1-C6)alkilena-, NR'R"C(O)- i (C3-C6)aril-(C3-C14)-cikloalkilena-,ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera;uz uslov da jedinjenje Formule I nije 1-amin-2-(3-borpropil)cikloheksan karboksilna kiselina.Prijava sadrži još 14 patentnih zahteva.
RS20160243A 2010-10-26 2011-10-19 Borati kao inhibitori arginaze RS54750B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40676010P 2010-10-26 2010-10-26
PCT/US2011/056844 WO2012058065A1 (en) 2010-10-26 2011-10-19 Boronates as arginase inhibitors
EP11779904.9A EP2632927B1 (en) 2010-10-26 2011-10-19 Boronates as arginase inhibitors

Publications (1)

Publication Number Publication Date
RS54750B1 true RS54750B1 (sr) 2016-10-31

Family

ID=44913403

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160243A RS54750B1 (sr) 2010-10-26 2011-10-19 Borati kao inhibitori arginaze

Country Status (19)

Country Link
US (5) US9233985B2 (sr)
EP (3) EP3034509B1 (sr)
JP (1) JP5909239B2 (sr)
CN (2) CN103249737B (sr)
AU (1) AU2011320732B2 (sr)
BR (1) BR112013010099B1 (sr)
CA (1) CA2815536C (sr)
DK (1) DK2632927T3 (sr)
ES (2) ES2568680T3 (sr)
HK (2) HK1223104A1 (sr)
HR (1) HRP20160305T1 (sr)
HU (1) HUE027317T2 (sr)
IL (1) IL225926A (sr)
MX (1) MX336381B (sr)
PL (1) PL2632927T3 (sr)
RS (1) RS54750B1 (sr)
SI (1) SI2632927T1 (sr)
SM (1) SMT201600141B (sr)
WO (1) WO2012058065A1 (sr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
PL2603514T3 (pl) 2010-08-10 2019-04-30 Rempex Pharmaceuticals Inc Cykliczne pochodne estrowe kwasu boronowego oraz ich zastosowania terapeutyczne
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
EP2852598B3 (en) * 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2944903A1 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP4356736A2 (en) 2014-05-05 2024-04-24 Melinta Therapeutics, Inc. Synthesis of boronate salts
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
RU2729379C1 (ru) 2015-10-01 2020-08-06 Потенза Терапевтикс, Инк. Анти-tigit антигенсвязывающие белки и способы их применения
KR20220118559A (ko) * 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
WO2018089490A1 (en) * 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
DK3559009T3 (da) 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
UY38096A (es) 2018-02-17 2019-07-31 Astrazeneca Ab Inhibidores de arginasa y sus métodos de uso
JP7402167B2 (ja) * 2018-03-05 2023-12-20 アーカス バイオサイエンシズ インコーポレイティド アルギナーゼ阻害剤
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
CN111770756B (zh) * 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3880685A4 (en) 2018-11-16 2022-07-27 Arcus Biosciences, Inc. ARG1 AND/OR ARG2 INHIBITORS
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
CR20210463A (es) * 2019-02-08 2021-10-15 Astrazeneca Ab Inhibidores de arginasa y métodos de uso de estos
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023283332A1 (en) * 2021-07-07 2023-01-12 Emory University Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
WO2023191116A2 (en) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Improved suramin methods and compositions
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009890A (en) 1911-02-09 1911-11-28 Michael F Brauer Dumping attachment for headers.
US1006597A (en) 1911-05-26 1911-10-24 Rail Joint Co Insulated rail-joint.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
CA2305703A1 (en) * 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
US20100056480A1 (en) 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
JP5386353B2 (ja) 2007-07-12 2014-01-15 山洋電気株式会社 二重反転式軸流送風機
EP2214660A2 (en) 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
DK2389352T3 (da) 2009-01-26 2019-07-29 Univ Pennsylvania Arginaseinhibitorer og anvendelsesfremgangsmåder
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2852598B3 (en) 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
BR112015010059A2 (pt) 2012-11-02 2017-07-11 Pharmacyclics Inc terapia adjuvante com inibidor da quinase da família tec
ES2719327T3 (es) 2013-07-01 2019-07-09 Bristol Myers Squibb Co Inhibidores de IDO
CN105848680A (zh) 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
KR20170129896A (ko) 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
KR20220118559A (ko) 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
DK3559009T3 (da) 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
CN106008569B9 (zh) 2020-05-22
US11389464B2 (en) 2022-07-19
SI2632927T1 (sl) 2016-08-31
HUE027317T2 (en) 2016-10-28
US20150191492A1 (en) 2015-07-09
HRP20160305T1 (hr) 2016-07-01
SMT201600141B (it) 2016-07-01
WO2012058065A1 (en) 2012-05-03
EP2632927A1 (en) 2013-09-04
US20120129806A1 (en) 2012-05-24
EP3034509B1 (en) 2020-04-22
HK1225390A1 (zh) 2017-09-08
ES2568680T3 (es) 2016-05-03
US9440995B2 (en) 2016-09-13
JP2013542223A (ja) 2013-11-21
JP5909239B2 (ja) 2016-04-26
US10098902B2 (en) 2018-10-16
CA2815536A1 (en) 2012-05-03
EP3719024A1 (en) 2020-10-07
US10603330B2 (en) 2020-03-31
US20200246362A1 (en) 2020-08-06
CN106008569B (zh) 2020-04-03
BR112013010099A2 (pt) 2016-09-06
IL225926A0 (en) 2013-06-27
PL2632927T3 (pl) 2016-09-30
IL225926A (en) 2016-09-29
AU2011320732B2 (en) 2018-07-05
CN103249737A (zh) 2013-08-14
US9233985B2 (en) 2016-01-12
US20190054101A1 (en) 2019-02-21
CN103249737B (zh) 2016-06-08
AU2011320732A1 (en) 2013-11-21
BR112013010099B1 (pt) 2021-08-10
EP2632927B1 (en) 2016-02-10
HK1223104A1 (zh) 2017-07-21
MX336381B (es) 2016-01-18
DK2632927T3 (en) 2016-04-11
MX2013004491A (es) 2013-11-04
EP3034509A1 (en) 2016-06-22
CN106008569A (zh) 2016-10-12
US20170000808A1 (en) 2017-01-05
ES2794006T3 (es) 2020-11-17
CA2815536C (en) 2019-10-01

Similar Documents

Publication Publication Date Title
RS54750B1 (sr) Borati kao inhibitori arginaze
RS54661B1 (sr) Supstituisani imidazopiridazini
MX2020010964A (es) Conjugado de anticuerpo-farmaco.
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
HRP20210562T1 (hr) Karbohidratni ligandi koji se vežu na igm antitijela koja djeluju protiv glikoproteina povezanog s mijelinom
BR112017011039A2 (pt) hidrogéis extintores de incêndio, aperfeiçoadores de água
BR112015026554A2 (pt) saco de contenção compreendendo uma composição detergente líquida
BR112013011827A2 (pt) ''respirador com peça facial filtrante que tem uma vedação facial moldada com sobreposição''
PH12014502337A1 (en) Method for absorbing co2 from a gas mixture
BR112015024274A2 (pt) agente antiestático, composição de agente antiestático, composição de resina antiestática e artigo moldado
AT514123A3 (de) Polysaccharidfilm und Verfahren zu seiner Herstellung
MX336777B (es) Peliculas y composiciones que comprenden las mismas.
DE602005023292D1 (de) Verfahren und system zur messung der geschwindigkeit einer blutströmung
BR112014013682B8 (pt) composição para cuidado pessoal
CL2013002565A1 (es) Composición granular dispersable en agua, que comprende en peso y respecto del total de la composición: a) entre 30-85% de azufre; b) entre 8-60% de sulfato de zinc monohidratado y c) un excipiente agroquímicamente aceptable, y donde los fránulos dispersables en agua comprende partículas entre 0,2 a 50 micrones.
MX341258B (es) Materiales dentales basados en compuestos con propiedades de despegado segun sea necesario.
CO6341634A2 (es) Nuevos derivados de imidazo(1,2-a)pirimidina, su procesamiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
BR112014026853A2 (pt) corante que absorve uv polimerizável estável para lente intraocular
DE602006008639D1 (de) Automatisches radioaktives markierungsverafhren
BR112014004263A2 (pt) composições fixadoras de cabelo
WO2007144512A3 (fr) Derivés diazeniumdiolates, leur procédé de préparation, leurs compositions pharmaceutiques et leur utilisation dans le domaine de l ' hypertension et des pathologies cardiovasculaires
MX2018005415A (es) Composicion formadora de pelicula dental duradera y usos de esta.
AR089270A1 (es) Pelicula que contiene composiciones, composicion para el cuidado oral, metodo para controlar la liberacion de un pigmento, para limpiar los dientes
AR080249A1 (es) Compuestos en calidad de antagonistas de bradiquinina-b1